313 related articles for article (PubMed ID: 31003195)
1. Quality of life in adults enrolled in an open-label study of cannabidiol (CBD) for treatment-resistant epilepsy.
Gaston TE; Szaflarski M; Hansen B; Bebin EM; Szaflarski JP;
Epilepsy Behav; 2019 Jun; 95():10-17. PubMed ID: 31003195
[TBL] [Abstract][Full Text] [Related]
2. Cannabidiol improves frequency and severity of seizures and reduces adverse events in an open-label add-on prospective study.
Szaflarski JP; Bebin EM; Cutter G; DeWolfe J; Dure LS; Gaston TE; Kankirawatana P; Liu Y; Singh R; Standaert DG; Thomas AE; Ver Hoef LW;
Epilepsy Behav; 2018 Oct; 87():131-136. PubMed ID: 30100226
[TBL] [Abstract][Full Text] [Related]
3. Long-term safety and efficacy of highly purified cannabidiol for treatment refractory epilepsy.
Gaston TE; Ampah SB; Martina Bebin E; Grayson LP; Cutter GR; Hernando K; Szaflarski JP;
Epilepsy Behav; 2021 Apr; 117():107862. PubMed ID: 33667843
[TBL] [Abstract][Full Text] [Related]
4. Cannabidiol normalizes resting-state functional connectivity in treatment-resistant epilepsy.
Nenert R; Allendorfer JB; Bebin EM; Gaston TE; Grayson LE; Houston JT; Szaflarski JP
Epilepsy Behav; 2020 Nov; 112():107297. PubMed ID: 32745959
[TBL] [Abstract][Full Text] [Related]
5. fMRI study of cannabidiol-induced changes in attention control in treatment-resistant epilepsy.
Allendorfer JB; Nenert R; Bebin EM; Gaston TE; Grayson LE; Hernando KA; Houston JT; Hansen B; Szaflarski JP
Epilepsy Behav; 2019 Jul; 96():114-121. PubMed ID: 31129526
[TBL] [Abstract][Full Text] [Related]
6. Cognitive functioning following long-term cannabidiol use in adults with treatment-resistant epilepsy.
Martin RC; Gaston TE; Thompson M; Ampah SB; Cutter G; Bebin EM; Szaflarski JP
Epilepsy Behav; 2019 Aug; 97():105-110. PubMed ID: 31220785
[TBL] [Abstract][Full Text] [Related]
7. Social correlates of health status, quality of life, and mood states in patients treated with cannabidiol for epilepsy.
Szaflarski M; Hansen B; Bebin EM; Szaflarski JP
Epilepsy Behav; 2017 May; 70(Pt B):364-369. PubMed ID: 28236578
[TBL] [Abstract][Full Text] [Related]
8. Drug-drug interactions with cannabidiol (CBD) appear to have no effect on treatment response in an open-label Expanded Access Program.
Gaston TE; Bebin EM; Cutter GR; Ampah SB; Liu Y; Grayson LP; Szaflarski JP;
Epilepsy Behav; 2019 Sep; 98(Pt A):201-206. PubMed ID: 31382177
[TBL] [Abstract][Full Text] [Related]
9. Cognitive function and adaptive skills after a one-year trial of cannabidiol (CBD) in a pediatric sample with treatment-resistant epilepsy.
Thompson MD; Martin RC; Grayson LP; Ampah SB; Cutter G; Szaflarski JP; Bebin EM
Epilepsy Behav; 2020 Oct; 111():107299. PubMed ID: 32759071
[TBL] [Abstract][Full Text] [Related]
10. Higher cannabidiol plasma levels are associated with better seizure response following treatment with a pharmaceutical grade cannabidiol.
Szaflarski JP; Hernando K; Bebin EM; Gaston TE; Grayson LE; Ampah SB; Moreadith R
Epilepsy Behav; 2019 Jun; 95():131-136. PubMed ID: 31048098
[TBL] [Abstract][Full Text] [Related]
11. Purified Cannabidiol for Treatment of Refractory Epilepsies in Pediatric Patients with Developmental and Epileptic Encephalopathy.
Pietrafusa N; Ferretti A; Trivisano M; de Palma L; Calabrese C; Carfì Pavia G; Tondo I; Cappelletti S; Vigevano F; Specchio N
Paediatr Drugs; 2019 Aug; 21(4):283-290. PubMed ID: 31179531
[TBL] [Abstract][Full Text] [Related]
12. Long-term safety and efficacy of cannabidiol in children and adults with treatment resistant Lennox-Gastaut syndrome or Dravet syndrome: Expanded access program results.
Laux LC; Bebin EM; Checketts D; Chez M; Flamini R; Marsh ED; Miller I; Nichol K; Park Y; Segal E; Seltzer L; Szaflarski JP; Thiele EA; Weinstock A;
Epilepsy Res; 2019 Aug; 154():13-20. PubMed ID: 31022635
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of cannabidiol in subjects with refractory epilepsy relative to concomitant use of clobazam.
Savage TE; Sourbron J; Bruno PL; Skirvin LA; Wolper ES; Anagnos CJ; Thiele EA
Epilepsy Res; 2020 Feb; 160():106263. PubMed ID: 31923763
[TBL] [Abstract][Full Text] [Related]
14. The effect of cannabidiol on seizure features and quality of life in drug-resistant frontal lobe epilepsy patients: a triple-blind controlled trial.
Ebadi SR; Saleki K; Adl Parvar T; Rahimi N; Aghamollaii V; Ranji S; Tafakhori A
Front Neurol; 2023; 14():1143783. PubMed ID: 37470002
[TBL] [Abstract][Full Text] [Related]
15. Highly purified cannabidiol in the treatment of drug-resistant epilepsies: A real-life impact on seizure frequency, quality of life, behavior, and sleep patterns from a single Italian center.
Ferrera G; Ricci E; Vignoli A; Savini MN; Viganò I; Chiesa V; Caputo D; Zambrelli E; La Briola F; Turner K; Canevini MP
Epilepsy Behav; 2023 Oct; 147():109409. PubMed ID: 37677907
[TBL] [Abstract][Full Text] [Related]
16. A preliminary study of the effects of cannabidiol (CBD) on brain structure in patients with epilepsy.
Sharma AA; Nenert R; Allendorfer JB; Gaston TE; Grayson LP; Hernando K; Szaflarski JP
Epilepsy Behav Rep; 2019; 12():100341. PubMed ID: 32322816
[TBL] [Abstract][Full Text] [Related]
17. Cannabidiol as a new treatment for drug-resistant epilepsy in tuberous sclerosis complex.
Hess EJ; Moody KA; Geffrey AL; Pollack SF; Skirvin LA; Bruno PL; Paolini JL; Thiele EA
Epilepsia; 2016 Oct; 57(10):1617-1624. PubMed ID: 27696387
[TBL] [Abstract][Full Text] [Related]
18. Long-term efficacy and safety of cannabidiol (CBD) in children with treatment-resistant epilepsy: Results from a state-based expanded access program.
Park YD; Linder DF; Pope J; Flamini JR; Moretz K; Diamond MP; Long SA
Epilepsy Behav; 2020 Nov; 112():107474. PubMed ID: 33181893
[TBL] [Abstract][Full Text] [Related]
19. Cannabidiol in treatment of refractory epileptic spasms: An open-label study.
Herlopian A; Hess EJ; Barnett J; Geffrey AL; Pollack SF; Skirvin L; Bruno P; Sourbron J; Thiele EA
Epilepsy Behav; 2020 May; 106():106988. PubMed ID: 32169600
[TBL] [Abstract][Full Text] [Related]
20. Long-term safety and treatment effects of cannabidiol in children and adults with treatment-resistant epilepsies: Expanded access program results.
Szaflarski JP; Bebin EM; Comi AM; Patel AD; Joshi C; Checketts D; Beal JC; Laux LC; De Boer LM; Wong MH; Lopez M; Devinsky O; Lyons PD; Zentil PP; Wechsler R;
Epilepsia; 2018 Aug; 59(8):1540-1548. PubMed ID: 29998598
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
